Tucuvi, a Spanish clinical voice AI startup, has raised $20 million in a Series A funding round to accelerate the expansion of its AI Care Management platform across Europe and the United States. The round was co-led by Cathay Innovation and Kfund, through its early-growth Leadwind fund, with participation from existing investors Frontline Ventures, Seaya Ventures, and Shilling. The investment highlights strong confidence in Tucuvi’s mission to use safe and scalable AI to support clinical care.
Founding Story Rooted in Personal Experience
The company was co-founded by CEO Maria Gonzalez and CTO Marcos Rubio. Gonzalez was inspired to create Tucuvi after her mother passed away following a reported hospital administration error. This experience led her to build technology designed to help hospitals reduce preventable mistakes and improve consistency in patient care, particularly in overburdened healthcare environments.
AI Platform Built for Clinical Workflows
Tucuvi’s central offering is an AI Care Management platform that automates and orchestrates high-volume clinical workflows from start to finish. At the core is LOLA, a voice AI agent capable of conducting natural phone conversations with patients. LOLA can perform clinical tasks, coordinate care steps, and escalate to human clinicians when needed. The system handles documentation, workflow execution, and integration with existing healthcare operations, ensuring smooth adoption.
Supports More Than 50 Clinical Use Cases
The platform already supports more than 50 clinical workflows, including post-surgical follow-ups, transitions of care, chronic disease management, pre-operative assessments, clinical screenings, scheduling, and medication management. Tucuvi says its agents can manage complex real-world interactions with patients, enabling consistent and guided conversations that follow evidence-based protocols.
Growing Deployment Across Europe
Tucuvi reports that it has completed more than 300,000 patient calls and is serving over 60 healthcare organisations across Europe. Its technology is used by hospitals, outpatient clinics, and chronic care programs that depend on reliable and timely communication with patients. With rising demand, the new funding will support broader European expansion as well as the company’s entry into the US market.
Focus on Trust, Safety, and Regulation
A key differentiator for Tucuvi is its emphasis on building AI systems that healthcare organisations can trust. The company has received European regulatory clearance as a Class IIb Software as a Medical Device for LOLA and its broader care management platform. This level of certification, uncommon among AI clinical tools, reflects Tucuvi’s commitment to safety, transparency, and auditability.
CEO’s Vision for Scalable Clinical Care
Maria Gonzalez said that healthcare systems are under immense pressure and that incremental improvements are no longer enough to keep pace with growing patient needs. She emphasised that the path forward depends on AI that can support clinical teams directly while ensuring that workflows remain safe and compliant. Gonzalez added that Tucuvi is proud to already serve a large and growing number of healthcare organisations and is accelerating rapidly to meet demand.
Positioned for Global Growth
With strong investor backing, a proven platform, and significant regulatory achievements, Tucuvi is well positioned to influence the future of AI-enabled healthcare operations. The company plans to expand its catalogue of clinical workflows, deepen integration across health systems, and add new capabilities that improve patient engagement, safety, and continuity of care. As health systems continue to search for solutions that expand capacity and improve outcomes, Tucuvi’s AI-driven platform aims to redefine how clinical care is delivered at scale.